Financial Contrast: Gossamer Bio (GOSS) and Its Peers

Gossamer Bio (NASDAQ:GOSS) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Gossamer Bio to related companies based on the strength of its profitability, valuation, analyst recommendations, risk, dividends, earnings and institutional ownership.

Earnings and Valuation

This table compares Gossamer Bio and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Gossamer Bio	$48.47 million	-$170.37 million	-0.18
Gossamer Bio Competitors	$727.61 million	$12.25 million	-10.38

Gossamer Bio’s competitors have higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Gossamer Bio has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Gossamer Bio’s competitors have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Gossamer Bio and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2	3	5	0	2.30
Gossamer Bio Competitors	9792	15072	45346	1574	2.54

Gossamer Bio presently has a consensus price target of $256.00, indicating a potential upside of 2,472.86%. As a group, “Biotechnology” companies have a potential upside of 92.13%. Given Gossamer Bio’s higher possible upside, equities analysts plainly believe Gossamer Bio is more favorable than its competitors.

Institutional and Insider Ownership

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 4.2% of Gossamer Bio shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Gossamer Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Gossamer Bio Competitors	-9,051.23%	-201.20%	-30.64%

Summary

Gossamer Bio competitors beat Gossamer Bio on 7 of the 12 factors compared.

Gossamer Bio Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.